Nutex Health (NUTX) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 16, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53862
Entity Registrant Name	Clinigence Holdings, Inc
Entity Central Index Key	0001479681
Entity Tax Identification Number	11-3363609
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2455 East Sunrise Blvd.
Entity Address, Address Line Two	Suite 1204
Entity Address, City or Town	Fort Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33304
City Area Code	678
Local Phone Number	607-6393
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	CLNH
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,047,261

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 4,795,175	$ 26,931
Accounts receivable	334,958	18,283
Prepaid expenses and other current assets	457,345	111,842
Total current assets	5,587,478	157,056
Long-term assets
Property and equipment, net	10,367	12,391
Right of use asset, net	119,495	0
Investment in ACMG	6,994,190	0
Intangible assets, net	9,461,825	0
Goodwill	55,182,186	0
Deposits and other assets	410	410
Total assets	77,355,951	169,857
Current liabilities
Accounts payable and accrued expenses	3,810,992	695,424
Customer deposits	25,326	38,651
Accrued interest on notes payable	319,276	0
Due to related parties	128,176	30,000
Lease liability - current	44,305
Deferred revenue	74,028	76,687
Convertible notes payable, net of debt discount	2,155,088	0
Current portion of notes payable	727,072	312,890
Total current liabilities	7,284,263	1,153,652
Long-term liabilities
Lease liability - long term	79,659
Deferred tax liabilities	2,429,500	0
Notes payable	300,000	150,000
Total liabilities	10,093,422	1,303,652
Stockholders' equity (deficiency)
Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2020 and 2019, respectively	0	0
Common stock, $.001 par value; authorized - 800,000,000 shares; 41,250,118 and 5,282,545 shares issued and outstandingas of June 30, 2021 and December 31, 2020, respectively	41,250	5,282
Additional paid-in capital	92,712,821	17,079,885
Accumulated deficit	(25,402,032)	(18,218,962)
Noncontrolling interest	(89,510)
Total stockholders' equity (deficiency)	67,262,529	(1,133,795)
Total liabilities and stockholders' equity (deficiency)	$ 77,355,951	$ 169,857

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	41,250,118	5,282,545
Common stock, shares outstanding	41,250,118	5,282,545

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Sales	$ 5,290,505	$ 378,588	$ 7,304,850	$ 844,218
Cost of sales	4,187,943	264,859	5,775,416	463,987
Gross profit	1,102,562	113,729	1,529,434	380,231
Operating expenses
Research and development	59,629	314,255	136,349	429,134
Sales and marketing	6,704	52,669	16,443	173,849
General and administrative expenses	1,780,972	1,341,701	6,207,264	2,177,753
Gain on sale of assets	0	(2,328,178)	0	(2,328,178)
Amortization	192,131	87,726	256,175	222,032
Total operating expenses	2,039,436	(531,827)	6,616,231	674,590
Income (loss) from operations	(936,874)	645,556	(5,086,797)	(294,359)
Other income (expenses)
Loss on disposal of subsidiary	0	(1,170)	0	(158,744)
Income from forgiveness of debt	314,807	0	314,807	0
Loss from earnings from equity investment	(139,810)	0	(139,810)	0
Loss on extinguishment of debt	0	(167,797)	0	(167,797)
Interest income	245	0	359	0
Interest expense	(2,026,808)	(249,283)	(2,361,139)	(314,276)
Total other income (expenses)	(1,851,566)	(418,250)	(2,185,783)	(640,817)
Income (loss) from continuing operations	(2,788,440)	227,306	(7,272,580)	(935,176)
Income from discontinued operations (including gain on disposal of $142,027 for the six months ended June 30, 2020)	0	0	0	39,752
Net income (loss)	(2,788,440)	227,306	(7,272,580)	(895,424)
Net loss attributable to noncontrolling interest	(49,929)	0	(89,510)	0
Net income (loss) attributable to Clinigence Holdings, Inc.	$ (2,738,511)	$ 227,306	$ (7,183,070)	$ (895,424)
Basic and fully diluted income (loss) per common share:
Continuing operations	$ (0.07)	$ 0.05	$ (0.25)	$ (0.20)
Discontinued operations				0.01
Net income (loss) per common share	$ (0.07)	$ 0.05	$ (0.25)	$ (0.19)
Weighted average common shares outstanding - basic and fully diluted	40,017,213	4,651,661	29,358,349	4,650,420

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical)	6 Months Ended
	Jun. 30, 2020USD ($)
Income Statement [Abstract]
Gain on disposal	$ 142,027

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 4,649	$ 14,422,579	$ (12,568,795)			$ 1,858,433
Beginning balance, Shares at Dec. 31, 2019	4,649,179
Stock-based compensation		848,778				848,778
Purchase of treasury stock					(1,170)	(1,170)
Net income			(1,122,730)			(1,122,730)
Ending balance, value at Mar. 31, 2020	$ 4,649	15,271,357	(13,691,525)		(1,170)	1,583,311
End balance, Shares at Mar. 31, 2020	4,649,179
Options issued for services		1,056,599				1,056,599
Stock-based compensation	$ 226	361,086				361,312
Treasury stock cancelled					1,170	1,170
Stock-based compensation, Shares	225,820
Net income			227,306			227,306
Ending balance, value at Jun. 30, 2020	$ 4,875	16,689,042	(13,464,219)			3,229,698
End balance, Shares at Jun. 30, 2020	4,874,999
Beginning balance, value at Dec. 31, 2020	$ 5,282	17,079,885	(18,218,962)			(1,133,795)
Beginning balance, Shares at Dec. 31, 2020	5,282,545
Stock-based compensation	$ 933	3,851,704				3,852,637
Stock-based compensation, Shares	932,567
Common stock issued for related party note	$ 46	29,054				30,000
Common stock issued for related party note, Shares	46,154
Common stock issued in business acquisitions	$ 33,034	68,017,978				68,051,012
Common stock issued in business acquisitions, Shares	33,034,466
Net income			(4,444,559)	(39,581)		(4,484,140)
Ending balance, value at Mar. 31, 2021	$ 39,295	88,979,521	(22,663,521)	(39,581)		66,315,714
End balance, Shares at Mar. 31, 2021	39,295,732
Net income			(2,738,511)	(49,929)		(2,788,440)
Common stock issued for cash	$ 1,826	3,193,174				3,195,000
Common stock issued for cash, Shares	1,825,714
Financing cost for capital raise		(319,500)				(319,500)
Notes payable converted to common stock	$ 129	199,871				200,000
Notes payable converted to common stock, Shares	128,672
Debt discount on notes payable		659,755				659,755
Ending balance, value at Jun. 30, 2021	$ 41,250	$ 92,712,821	$ (25,402,032)	$ (89,510)		$ 67,262,529
End balance, Shares at Jun. 30, 2021	41,250,118

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,272,580)	$ (895,424)
(Income) loss from discontinued operations	0	(39,752)
Net loss from continuing operations	(7,272,580)	(935,176)
Adjustments to reconcile net loss to netcash used in operating activities
Depreciation	2,024	9,081
Amortization	266,651	82,633
Interest expense associated with debt discount	1,894,828	0
Non cash interest expense	24,372	474,344
Gain on sale of assets	0	(2,328,178)
Loss on extinguishment of debt	0	167,797
Income from forgiveness of debt	(311,125)	0
Loss from earnings from equity investment	139,810	0
Stock-based compensation expense	3,852,637	2,266,690
Changes in operating assets and liabilities:
Accounts receivable	(47,360)	(35,901)
Prepaid expenses and other current assets	(317,225)	(128,913)
Deposits and other assets	0	(410)
Accounts payable and accrued expenses	(964,523)	(758,100)
Customer deposits	(13,325)	0
Accrued interest on notes payable	361,807	(27,335)
Lease liability	(6,007)	(24,613)
Deferred revenue	(2,659)	(130,148)
NET CASH USED IN OPERATING ACTIVITIES	(2,392,675)	(1,368,229)
CASH FLOWS FROM INVESTING ACTIVITIES:
Preacquisition loans from subsidiary	85,000	0
Cash acquired from acquisition of subsidiary	3,803,267
Net cash provided by continuing investing activities	3,888,267
Net cash used in discontinued investing activities		(2,656)
NET CASH PROVIDED BY (USED) IN INVESTING ACTIVITIES	3,888,267	(2,656)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	3,195,000
Payments on note receivable - related party	0	0
Proceeds from notes payable	413,917	461,125
Payments on notes payable	(16,765)	(92,052)
Payments of financing costs for capital raise	(319,500)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,272,652	369,073
NET INCREASE (DECREASE) IN CASH	4,768,244	(1,001,812)
CASH - BEGINNING OF PERIOD	26,931	1,065,434
CASH - END OF PERIOD	4,795,175	63,622
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest	289,812	9,130
Non-cash investing and financing activities:
Investment in AHA in exchange of assets sold and liabilities assumed	0	6,402,278
Common stock issued for acquisition of subsidiaries	68,051,012	0
Related party loans converted to common stock	30,000	0
Notes payable converted to accounts payable	228,518	0
Notes payable converted to common stock	200,000
Accrued interest converted to convertible notes payable	54,746	0
Deferred tax liability recorded on intangible assets	2,429,500	0
Debt discount on notes payable	659,755
Right of use asset added for operating lease	$ 129,971	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation The consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the “Company”) and its wholly-owned subsidiaries, Accountable Healthcare America, Inc. (“AHA”), AHP Management, Inc. (“AHP”), Clinigence Health, Inc. (“Clinigence”) and HealthDatix, Inc. (“HealthDatix”). The Company’s name was changed to Clinigence Holdings, Inc. on October 29, 2019 in connection with a reverse merger. In October 2018, Clinigence was incorporated as a wholly-owned subsidiary of Clinigence LLC. The Company is a population health analytics company that provides turnkey SaaS solutions that enable connected intelligence across the care continuum by transforming massive amounts of data into actionable insights. The Company’s solutions help healthcare organizations throughout the United States improve the quality and cost-effectiveness of care, enhance population health management and optimize provider networks. The Company enables risk-bearing healthcare organizations achieve their objectives on the path to value-based care. The Company’s platform automatically extracts and delivers targeted data insights from its cloud-based analytics engine directly to the workflows and technologies of its customers. This enhances end-user workflows with actionable analytics, seamlessly delivers data from disparate sources to the point of engagement, automates the delivery of data to ensure on-time access, and reduces dependency on non-essential applications from the end-user’s workflow. All of this allows the healthcare organization to enable population health management, manage cost and utilization, improve quality, identify gaps in care, risk stratify and target patients, increase collaboration among providers and to optimize network provider performance. AHA was organized to acquire a series of companies providing a broad array of health and managed care services to Medicare members. AHA’s initial focus is on acquiring Accountable Care Organizations (“ACO’s”), Managed Service Organizations (“MSO’s”) and Primary Care Physician Practices (“PCP’s”) with significant numbers of Medicare members. Interim Financial Statements The following (a) condensed consolidated balance sheet as of December 31, 2020, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 5, 2021. Business Acquisitions Merger With AHP Management Inc. On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), AHP, Inc., a California corporation (“AHP”), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”), and Robert Chan (the “Shareholders’ Representative”) entered into an agreement and plan of merger (the “AHP Merger Agreement”). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021 (the “AHP Closing”). The AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, h ereafter referred to as the “AHP Acquisition.” AHP was a privately held company with controlling interest in its’ affiliate Associated Hispanic Physicians of Southern California IPA, a California Medical corporation, (“AHPIPA”). A key term of the AHP Merger Agreement is that at Closing, AHP Management Inc entered into a Management Services Agreement with AHPIPA (the “Management Services Agreements”) making AHPIPA a Variable Interest Entity (VIE) of Clinigence. Merger With Accountable Healthcare America, Inc. On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), Accountable Healthcare America, Inc., a Delaware corporation (“AHA”), and AHA Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”) entered into an agreement and plan of merger (the “AHA Merger Agreement”). The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the “AHA Closing”). The AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, h ereafter referred to as the “AHA Acquisition.” Pursuant to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at $2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing, the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. The following table presents the preliminary allocation of the value of the common shares issued for AHA to the acquired identifiable assets, liabilities assumed and goodwill: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 697,191 Other current assets 2,100 Investment in ACMG 7,134,000 PHP technology 2,729,000 Loan to Clinigence 85,000 Accounts payable (1,143,106 ) Due to related party (128,176 ) Notes payable (1,631,942 ) Convertible notes payable — Goodwill 21,115,272 Purchase price $ 28,859,339 The following table presents the preliminary allocation of the value of the common shares issued for AHP to the acquired identifiable assets, liabilities assumed and goodwill: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 3,105,877 Accounts receivable 269,315 Deposits and other assets 26,178 Member relationships 6,444,000 Trademarks 545,000 Accounts payable (2,683,896 ) Goodwill 31,433,526 Purchase price $ 39,140,000

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2021
Discontinued Operations
Discontinued Operations	Note 2 – Discontinued Operations Sale of Business On April 21, 2020 (effective March 1, 2020) the Company completed the sale of HealthDatix, Inc., a Florida corporation (“HDX FL”) to Jerry Robinson, Mary-Jo Robinson and Kathleen Shepherd (“HDX Management”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and HDX Management. Pursuant to the Purchase Agreement, the total consideration paid for the outstanding capital stock of HDX FL was the execution of Settlement and Release Agreements by HDX Management, releasing the Company from all obligations pursuant to certain HDX Management Employment Agreements dated April 1, 2017, and remittance of 1,000 shares of HDX common stock previously issued to HDX Management. As per the Purchase Agreement, the Company’s operations of HDX FL ended February 29, 2020 and HDX Management’s operation of the business is effective as of March 1, 2020. The components of loss from discontinued operations presented in the consolidated statements of operations for the six months ended June 30, 2021 are presented as follows: Schedule of consolidated statements of operations Sales $ 5,958 Cost of sales (6,795 ) General and administrative expenses (101,100 ) Depreciation and amortization (75 ) Interest expense (263 ) Loss from operations (102,275 ) Gain on disposal of HealthDatix 142,027 Income from discontinued operations $ 39,752

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable Healthcare America Inc., AHP Management Inc., and HealthDatix Inc. All intercompany accounts and transactions have been eliminated. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: •The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and •The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: 1.The entity does not have sufficient equity to finance its activities without additional subordinated financial support; 2. The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or 3. The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: a. The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: i. Substantive participating rights in day-to-day management of the entity’s activities; or ii. Substantive kick-out rights over the party responsible for significant decisions; iii. The obligation to absorb the entity’s expected losses; or iv. The right to receive the entity’s expected residual returns. If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Revenue Recognition Revenue is generated primarily by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. On January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied. The Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services. The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations in the contract; and 5. Recognizing revenue when (or as) the Company satisfies its performance obligations. Revenues from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers. AHA’s performance obligation is to manage ACO participants who provide healthcare services to CMS’s members for the purpose of generating shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment within ten months after the fiscal year-end. AHP negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The IPA recognizes capitation payments received in advance from third-party insurers as revenue on a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished. Advertising Costs The Company expenses advertising costs as incurred. Advertising costs of $ 16,444 33,791 Cash and Cash Equivalents Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of June 30, 2021 and December 31, 2020. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment. Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5 Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Trademarks 6 Goodwill Goodwill represents the excess of assets acquired over liabilities assumed of AHA and AHP and the fair market value of the common shares issued by the Company for the acquisition of AHA and AHP. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. No impairment was recorded during the six months ended June 30, 2021. Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows. Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $ 74,028 76,687 Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements . Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 4 – Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $ 25,402,032 1,696,785 As a result of the spread of the COVID-19 coronavirus, economic uncertainties have arisen which are likely to negatively impact operations. Other financial impact could occur though such potential impact is unknown at this time. A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, may not only impact our operations, financial condition and demand for our goods and services but our overall ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment Property and equipment are carried at cost and consist of the following at June 30, 2021 and December 31, 2020: Schedule of property, plant and equipment 2021 2020 Office equipment and fixtures $ 5,300 $ 5,300 Computer hardware 41,065 41,065 Computer software 16,121 16,121 Less: Accumulated depreciation (52,119 ) (50,095 ) Property, Plant and Equipment, Net $ 10,367 $ 12,391 Depreciation expense of $ 2,024 9,081

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6 – Intangible Assets The following tables provide detail associated with the Company’s acquired identifiable intangible assets: Schedule of intangible assets As of June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 6,444,000 $ (143,200 ) $ 6,300,800 15 Trademarks 545,000 (30,278 ) 514,722 6 PHP technology 2,729,000 (82,697 ) 2,646,303 11 Total $ 9,718,000 $ (256,175 ) $ 9,461,825 Aggregate Amortization Expense: For the six months ended June 30, 2021 $ 256,175

Investment in ACMG

Investment in ACMG	6 Months Ended
	Jun. 30, 2021
Investments, All Other Investments [Abstract]
Investment in ACMG	Note 7 – Investment in ACMG In connection with the acquisition of Accountable Care Medical Group of Florida, Inc. (“ACMG”), AHA defaulted on its payment obligations of $ 15,000,000 29 7,134,000 139,810 6,994,190

Operating Lease

Operating Lease	6 Months Ended
	Jun. 30, 2021
Operating Lease
Operating Lease	Note 8 – Operating Lease The Company determines if a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company's consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations, net of current portion in the Company's unaudited consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of one year or less are generally not included in ROU assets and liabilities. Operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheet as follows: Schedule Operating lease ROU assets and operating lease liabilities June 30, 2021 Operating Lease: Operating lease right-of-use assets, net $ 119,495 Current portion of operating lease liabilities 44,305 Operating lease liabilities, net of current portion 79,659 As of June 30, 2021, the weighted-average remaining lease term of the operating lease was 2.6 6.75 The following table summarizes maturities of operating lease liabilities based on lease term as of June 30, 2021: Schedule summarizes maturities of operating lease liabilities 2021 $ 25,229 2022 51,800 2023 53,354 2024 4,457 Total lease payments 134,840 Less: Imputed interest 10,876 Present value of lease liabilities $ 123,964 At June 30, 2021, the Company had the following future minimum payments due under the non-cancelable lease: Schedule minimum payments due under the non-cancelable lease 2021 $ 25,229 2022 51,800 2023 53,354 2024 4,457 Total minimum lease payments $ 134,840 Consolidated rental expense from continuing operations for all operating leases was $ 47,985 49,617 The following table summarizes the cash paid and related right-of-use operating lease recognized for the six months ended June 30, 2021. Schedule of cash paid and related right-of-use operating lease recognized Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 25,085 Right-of-use lease assets obtained in the exchange for lease liabilities: Operating leases 6,007

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2021
Basic and fully diluted income (loss) per common share:
Earnings (Loss) Per Common Share	Note 9 - Earnings (Loss) Per Common Share The Company calculates net income (loss) per common share in accordance with ASC 260 “ Earnings Per Share Computation of diluted net income (loss) per share Six Months Ended June 30, 2021 2020 Stock options 2,890,431 1,174,814 Stock warrants 8,434,409 557,873 Total shares excluded from calculation 11,324,840 1,732,687

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	Note 10 – Stock Based Compensation Options In 2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019 Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a four year period. Stock option activity during the six months ended June 30, 2021 and 2020 follows: Schedule of stock option activities Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2019 48,854 $ 5.11 8.05 Options granted 1,130,734 1.49 Options expired (400 ) 0.01 Options cancelled (4,374 ) 5.56 Options outstanding at June 30, 2020 1,174,814 $ 1.61 8.61 Options outstanding at December 31, 2020 1,174,814 $ 1.61 8.11 Options granted 1,225,000 1.61 Options assumed in merger 490,617 2.00 Options outstanding at June 30, 2021 2,890,431 $ 1.68 7.39 Options outstanding at June 30, 2021 consist of: Schedule of stock options outstanding Date Number Number Exercise Expiration Issued Outstanding Exercisable Price Date August 5, 2019 40,480 40,480 $ 5.56 August 5, 2029 October 29, 2019 3,600 3,600 $ 0.0725 June 6, 2027 January 27, 2020 307,884 307,884 $ 1.50 January 27, 2030 January 27, 2020 225,000 225,000 $ 1.50 January 27, 2027 February 29, 2020 95,794 95,794 $ 1.25 February 28, 2030 May 11, 2020 380,000 380,000 $ 1.50 May 11, 2027 June 30, 2020 122,056 122,056 $ 1.45 June 30, 2030 January 28, 2021 1,000,000 1,000,000 $ 1.61 January 28, 2031 January 28, 2021 225,000 225,000 $ 1.61 January 28, 2028 February 25, 2021 290,617 290,617 $ 2.00 March 15, 2025 February 25, 2021 200,000 200,000 $ 2.00 February 25, 2031 Total 2,890,431 2,890,431 Warrants In 2018, the Company issued fully vested warrants to investors as part of a private placement offering. Each unit offered in the private placement consisted of one share of common stock, and a warrant convertible into 0.4 shares of common stock at an exercise of $1.50 per whole share. The warrants are exercisable for a period of five years from the date of issuance. The warrants were cancelled on March 1, 2019 and reissued upon the Qualmetrix acquisition and are each convertible into one share of common stock at an exercise price of $6.67 per share until December 31, 2024. In November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal at an exercise price of $5.56 per share with an expiration date of October 31, 2025. Warrant activity during the six months ended June 30, 2021 and 2020 follows: Schedule of Warrants, Activity Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2019 1,065,251 $ 6.04 5.17 Warrants cancelled (507,378 ) — Warrants outstanding at June 30, 2020 557,873 $ 6.77 4.29 Warrants outstanding at December 31, 2020 557,873 $ 6.77 3.79 Warrants granted 1,460,571 1.75 Warrants assumed in merger 6,415,965 1.74 Warrants outstanding at June 30, 2021 8,434,409 $ 2.07 4.91 Warrants outstanding at June 30, 2021 consist of: Schedule of Outstanding Warrants Date Number Number Exercise Expiration Issued Outstanding Exercisable Price Date March 21, 2019 96,433 96,433 $ 6.67 December 31, 2024 April 30, 2019 3,598 3,598 $ 6.67 December 31, 2024 May 13, 2019 14,393 14,393 $ 6.67 December 31, 2024 May 28, 2019 199,703 199,703 $ 6.67 December 31, 2024 June 5, 2019 7,197 7,197 $ 6.67 December 31, 2024 June 25, 2019 208,361 208,361 $ 6.67 December 31, 2024 September 6, 2019 25,188 25,188 $ 6.67 December 31, 2024 October 29, 2019 1,500 1,500 $ 25.00 February 5, 2023 October 29, 2019 1,500 1,500 $ 25.00 April 27, 2023 February 25, 2021 1,666,573 1,666,573 $ 1.55 October 31, 2025 February 25, 2021 48,750 48,750 $ 1.25 October 31, 2025 February 25, 2021 500,000 500,000 $ 4.00 February 26, 2026 February 25, 2021 1,506,452 1,506,452 $ 1.55 February 1, 2027 February 25, 2021 2,694,190 2,694,190 $ 1.55 July 31, 2026 May 14, 2021 651,429 651,429 $ 1.75 May 31, 2027 May 28, 2021 228,571 228,571 $ 1.75 May 31, 2027 June 11, 2021 182,857 182,857 $ 1.75 May 31, 2027 June 22, 2021 137,143 137,143 $ 1.75 May 31, 2027 June 24, 2021 169,143 169,143 $ 1.75 May 31, 2027 June 28, 2021 45,714 45,714 $ 1.75 May 31, 2027 June 29, 2021 45,714 45,714 $ 1.75 May 31, 2027 Total 8,434,409 8,434,409

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2021
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Convertible notes payable consisted of the following at June 30, 2021 and December 31, 2020: Schedule of Convertible notes payable 2021 2020 Notes payable convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $1,780,088 and $0, respectively; maturing in July 2022 $ 1,580,088 $ — Note payable convertible into Clinigence common shares bearing interest at a rate of 12% 575,000 — Total convertible notes payable $ 2,155,088 $ — Included in the liabilities assumed in the AHA merger are convertible promissory notes to various individuals totaling $ 1,580,088 7,565,375 1.55 The debt discount of $ 7,565,375 1,580,088 200,000 128,672 At the time of issuance of these notes based on independent valuation, debt discounts were calculated and allocated based on the relative values of $ 2,658,960 4,906,415 3,703,134 1,086,095 Included in the liabilities assumed in the AHA merger are convertible promissory notes to an individual investor totaling $ 575,000 The note was entered into on August 25, 2020 and was convertible into AHA’s common stock contingent upon a merger transaction with a SPAC, which did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313 shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. As of the date of this report, the Note has not been converted. The Company and the noteholder are renegotiating the terms of the Note.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 12 – Notes Payable Notes payable consisted of the following at June 30, 2021 and December 31, 2020: Notes payable 2021 2020 Notes payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between 24% and 31% — 1,765 SBA Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest rate of 1% 432,087 311,125 SBA Economic Injury Disaster Loan notes payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75% 300,000 150,000 Note payable with a maturity date of January 31, 2023 and interest rate of 12.9% 294,985 — Total notes payable 1,027,072 462,890 Total notes payable, net $ 300,000 $ 150,000 Beginning in April 2018, the Company entered into a series of short-term notes with interest rates ranging from 24 31 8,200 0 1,765 The Company’s long-term debt is comprised of promissory notes pursuant to the Paycheck Protection Program and Economic Injury Disaster Loan (see below), under Coronavirus Aid, Relief and Economic Security Act (“CARES ACT”) enacted on March 27, 2020 and revised under the provisions of the PayCheck Protection Flexibility Act of 2020 on June 5, 2020 and administered by the United States Small Business Administration (“SBA”). On May 22, 2020, the Company received loan proceeds of $ 150,000 U.S. Small Business Administration (“SBA”) COVID-19 Economic Injury Disaster Loan On April 21, 2020, the Company received a loan in the amount of $ 311,125 260,087 1 Under the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll, rent and utilities during a designated twenty-four week period. Payments are deferred until the SBA determines the amount to be forgiven. The Company has utilized the proceeds of the PPP loan in a manner which has enabled qualification as a forgivable loan. However, no assurance can be provided that all or any portion of the PPP loans will be forgiven. AHA’s PPP loan of $ 172,000 432,087 311,125 The Company assumed a note payable in the AHA merger transaction that AHA entered into with an individual investor on October 24, 2019. AHA issued a note with a principal amount of $ 700,000 50,000 1.55 12.9 April 29, 2021 Effective February 1, 2021, an Amended and Restated Note was entered into in which the principal amount increased to $ 840,000 12.9 840,000 294,985

Stock Transactions

Stock Transactions	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stock Transactions	Note 13 – Stock Transactions Common Stock Issued The Company sold 1,825,714 1.75 3,195,000 319,500 547,715 In connection with the convertible notes payable (see Note 11 above) various noteholders converted $ 200,000 128,672 In connection with the acquisition of AHA the Company issued 14,034,472 2.06 In connection with the acquisition of AHP the Company issued 19,000,000 2.06 In connection with the AHA and AHP acquisitions, the Company issued 750,000 2.06 On January 28, 2021, the Company issued 228,721 153,606 .65

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 - Income Taxes A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets. A deferred tax liability of $ 2,429,500

Concentrations and Credit Risk

Concentrations and Credit Risk	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Concentrations and Credit Risk	Note 15 – Concentrations and Credit Risk Sales and Accounts Receivable The Company had sales to two customers which accounted for approximately 22 19 The Company had sales to one customer which accounted for approximately 12 14 Cash Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $ 250,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 16 - Related Party Transactions Due to Related Parties Due to related parties with a balance of $ 128,176 30,000 128,176 30,000 January 28, 2021

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17 – Commitments and Contingencies Employment Arrangements With Executive Officers The Company entered into 3-year employment agreements with Elisa Luqman and Dr. Lawrence Schimmel. Pursuant to the employment agreements with Ms. Luqman and Dr. Schimmel, each is entitled to receive a base annual salary of $ 150,000 180,000 250,000 250,000 150,000 250,000 Pursuant to the employment agreements with the named officers, upon termination, each such individual would be entitled to receive payment of all salary and benefits accrued up to the termination date of his or her employment in all employment termination events. Thereafter, Ms. Luqman would be entitled to receive twelve (12) months of base salary as a severance payment, Dr. Schimmel would be entitled to receive twenty-four (24) months of base salary as a severance payment, Dr. Hosseinion would be entitled to receive twenty four (24) months of base salary as a severance payment, Mr. Sternberg would be entitled to receive twenty four (24) months of base salary as a severance payment Mr. Bowen would be entitled to receive twelve (12) months of base salary as a severance payment, and Mr. Barnett would each be entitled to the balance of the remaining months under his employment agreement of base salary as a severance payment, upon termination of his or her employment by the Company without cause or by such individual for good reason. Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $ 75,000

Variable Interest Entities (VIE

Variable Interest Entities (VIEs)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities (VIEs)	Note 18 - Variable Interest Entities (VIEs) A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE. The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment. The following table includes assets that can only be used to settle the liabilities of AHPIPA and the creditors of AHPIPA have no recourse to the Company. These assets and liabilities are included in the accompanying consolidated balance sheets. Schedule of consolidated balance sheets June 30, 2021 ASSETS Current Assets Cash and cash equivalents $ 2,703,028 Accounts receivable 259,457 Prepaid expenses and other assets 100,281 Total Current Assets 3,062,766 Other Assets Goodwill 31,433,526 Right of use asset, net 119,495 Intangible assets, net 6,815,522 Total Other Assets 38,368,543 Total Assets $ 41,431,309 Current Liabilities Accounts payable and accrued expenses $ 2,256,856 Lease liability - current 44,305 Total Current Liabilities 2,301,161 Long-term Liabilities Lease liability – long-term 79,659 Total Liabilities $ 2,380,820

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events The Company evaluated its June 30, 2021 condensed consolidated financial statements for subsequent events through the date the condensed consolidated financial statements were issued. Common Stock Issued Subsequent to the end of the period through the date of the report, the Company sold 797,143 1.75 1,395,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable Healthcare America Inc., AHP Management Inc., and HealthDatix Inc. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Variable Interest Entities	Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: •The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and •The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: 1.The entity does not have sufficient equity to finance its activities without additional subordinated financial support; 2. The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or 3. The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: a. The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: i. Substantive participating rights in day-to-day management of the entity’s activities; or ii. Substantive kick-out rights over the party responsible for significant decisions; iii. The obligation to absorb the entity’s expected losses; or iv. The right to receive the entity’s expected residual returns. If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.
Fair Value Measurements	Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. The Company’s investment in AHA was valued at level 3 input. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
Revenue Recognition	Revenue Recognition Revenue is generated primarily by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. On January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially all the Company’s contracts with customers continues to be recognized over time as performance obligations are satisfied. The Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services. The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations in the contract; and 5. Recognizing revenue when (or as) the Company satisfies its performance obligations. Revenues from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the Company’s performance obligations and recognized over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly basis and does not provide any refunds, rights of return, or warranties to its customers. AHA’s performance obligation is to manage ACO participants who provide healthcare services to CMS’s members for the purpose of generating shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment within ten months after the fiscal year-end. AHP negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The IPA recognizes capitation payments received in advance from third-party insurers as revenue on a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished.
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. Advertising costs of $ 16,444 33,791
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of June 30, 2021 and December 31, 2020. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.
Accounts Receivable	Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.
Property and equipment and depreciation	Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5
Amortization	Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Trademarks 6
Goodwill	Goodwill Goodwill represents the excess of assets acquired over liabilities assumed of AHA and AHP and the fair market value of the common shares issued by the Company for the acquisition of AHA and AHP. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. No impairment was recorded during the six months ended June 30, 2021.
Long-Lived Assets	Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.
Deferred Revenue	Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $ 74,028 76,687
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity,
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements .
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2021
A H A [Member]
Entity Listings [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 697,191 Other current assets 2,100 Investment in ACMG 7,134,000 PHP technology 2,729,000 Loan to Clinigence 85,000 Accounts payable (1,143,106 ) Due to related party (128,176 ) Notes payable (1,631,942 ) Convertible notes payable — Goodwill 21,115,272 Purchase price $ 28,859,339
A H P [Member]
Entity Listings [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Fair Value Cash $ 3,105,877 Accounts receivable 269,315 Deposits and other assets 26,178 Member relationships 6,444,000 Trademarks 545,000 Accounts payable (2,683,896 ) Goodwill 31,433,526 Purchase price $ 39,140,000

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2021
Discontinued Operations
Schedule of consolidated statements of operations	Schedule of consolidated statements of operations Sales $ 5,958 Cost of sales (6,795 ) General and administrative expenses (101,100 ) Depreciation and amortization (75 ) Interest expense (263 ) Loss from operations (102,275 ) Gain on disposal of HealthDatix 142,027 Income from discontinued operations $ 39,752

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Schedule of estimated lives of respective assets	Schedule of estimated lives of respective assets Office equipment and fixtures 5 7 Computer hardware 5 Computer software 3 Development equipment 5
Schedule of estimated lives of the respective assets	Schedule of estimated lives of the respective assets Population Health Platform technology 11 Member relationships 15 Trademarks 6

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment 2021 2020 Office equipment and fixtures $ 5,300 $ 5,300 Computer hardware 41,065 41,065 Computer software 16,121 16,121 Less: Accumulated depreciation (52,119 ) (50,095 ) Property, Plant and Equipment, Net $ 10,367 $ 12,391

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets As of June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 6,444,000 $ (143,200 ) $ 6,300,800 15 Trademarks 545,000 (30,278 ) 514,722 6 PHP technology 2,729,000 (82,697 ) 2,646,303 11 Total $ 9,718,000 $ (256,175 ) $ 9,461,825

Operating Lease (Tables)

Operating Lease (Tables)	6 Months Ended
	Jun. 30, 2021
Operating Lease
Schedule Operating lease ROU assets and operating lease liabilities	Schedule Operating lease ROU assets and operating lease liabilities June 30, 2021 Operating Lease: Operating lease right-of-use assets, net $ 119,495 Current portion of operating lease liabilities 44,305 Operating lease liabilities, net of current portion 79,659
Schedule summarizes maturities of operating lease liabilities	Schedule summarizes maturities of operating lease liabilities 2021 $ 25,229 2022 51,800 2023 53,354 2024 4,457 Total lease payments 134,840 Less: Imputed interest 10,876 Present value of lease liabilities $ 123,964
Schedule minimum payments due under the non-cancelable lease	Schedule minimum payments due under the non-cancelable lease 2021 $ 25,229 2022 51,800 2023 53,354 2024 4,457 Total minimum lease payments $ 134,840
Schedule of cash paid and related right-of-use operating lease recognized	Schedule of cash paid and related right-of-use operating lease recognized Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 25,085 Right-of-use lease assets obtained in the exchange for lease liabilities: Operating leases 6,007

Earnings (Loss) Per Common Sh_2

Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2021
Basic and fully diluted income (loss) per common share:
Computation of diluted net income (loss) per share	Computation of diluted net income (loss) per share Six Months Ended June 30, 2021 2020 Stock options 2,890,431 1,174,814 Stock warrants 8,434,409 557,873 Total shares excluded from calculation 11,324,840 1,732,687

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activities	Schedule of stock option activities Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2019 48,854 $ 5.11 8.05 Options granted 1,130,734 1.49 Options expired (400 ) 0.01 Options cancelled (4,374 ) 5.56 Options outstanding at June 30, 2020 1,174,814 $ 1.61 8.61 Options outstanding at December 31, 2020 1,174,814 $ 1.61 8.11 Options granted 1,225,000 1.61 Options assumed in merger 490,617 2.00 Options outstanding at June 30, 2021 2,890,431 $ 1.68 7.39
Schedule of stock options outstanding	Schedule of stock options outstanding Date Number Number Exercise Expiration Issued Outstanding Exercisable Price Date August 5, 2019 40,480 40,480 $ 5.56 August 5, 2029 October 29, 2019 3,600 3,600 $ 0.0725 June 6, 2027 January 27, 2020 307,884 307,884 $ 1.50 January 27, 2030 January 27, 2020 225,000 225,000 $ 1.50 January 27, 2027 February 29, 2020 95,794 95,794 $ 1.25 February 28, 2030 May 11, 2020 380,000 380,000 $ 1.50 May 11, 2027 June 30, 2020 122,056 122,056 $ 1.45 June 30, 2030 January 28, 2021 1,000,000 1,000,000 $ 1.61 January 28, 2031 January 28, 2021 225,000 225,000 $ 1.61 January 28, 2028 February 25, 2021 290,617 290,617 $ 2.00 March 15, 2025 February 25, 2021 200,000 200,000 $ 2.00 February 25, 2031 Total 2,890,431 2,890,431
Schedule of Warrants, Activity	Schedule of Warrants, Activity Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2019 1,065,251 $ 6.04 5.17 Warrants cancelled (507,378 ) — Warrants outstanding at June 30, 2020 557,873 $ 6.77 4.29 Warrants outstanding at December 31, 2020 557,873 $ 6.77 3.79 Warrants granted 1,460,571 1.75 Warrants assumed in merger 6,415,965 1.74 Warrants outstanding at June 30, 2021 8,434,409 $ 2.07 4.91
Schedule of Outstanding Warrants	Schedule of Outstanding Warrants Date Number Number Exercise Expiration Issued Outstanding Exercisable Price Date March 21, 2019 96,433 96,433 $ 6.67 December 31, 2024 April 30, 2019 3,598 3,598 $ 6.67 December 31, 2024 May 13, 2019 14,393 14,393 $ 6.67 December 31, 2024 May 28, 2019 199,703 199,703 $ 6.67 December 31, 2024 June 5, 2019 7,197 7,197 $ 6.67 December 31, 2024 June 25, 2019 208,361 208,361 $ 6.67 December 31, 2024 September 6, 2019 25,188 25,188 $ 6.67 December 31, 2024 October 29, 2019 1,500 1,500 $ 25.00 February 5, 2023 October 29, 2019 1,500 1,500 $ 25.00 April 27, 2023 February 25, 2021 1,666,573 1,666,573 $ 1.55 October 31, 2025 February 25, 2021 48,750 48,750 $ 1.25 October 31, 2025 February 25, 2021 500,000 500,000 $ 4.00 February 26, 2026 February 25, 2021 1,506,452 1,506,452 $ 1.55 February 1, 2027 February 25, 2021 2,694,190 2,694,190 $ 1.55 July 31, 2026 May 14, 2021 651,429 651,429 $ 1.75 May 31, 2027 May 28, 2021 228,571 228,571 $ 1.75 May 31, 2027 June 11, 2021 182,857 182,857 $ 1.75 May 31, 2027 June 22, 2021 137,143 137,143 $ 1.75 May 31, 2027 June 24, 2021 169,143 169,143 $ 1.75 May 31, 2027 June 28, 2021 45,714 45,714 $ 1.75 May 31, 2027 June 29, 2021 45,714 45,714 $ 1.75 May 31, 2027 Total 8,434,409 8,434,409

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Convertible Notes Payable
Schedule of Convertible notes payable	Schedule of Convertible notes payable 2021 2020 Notes payable convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $1,780,088 and $0, respectively; maturing in July 2022 $ 1,580,088 $ — Note payable convertible into Clinigence common shares bearing interest at a rate of 12% 575,000 — Total convertible notes payable $ 2,155,088 $ —

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Notes payable	Notes payable 2021 2020 Notes payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between 24% and 31% — 1,765 SBA Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest rate of 1% 432,087 311,125 SBA Economic Injury Disaster Loan notes payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75% 300,000 150,000 Note payable with a maturity date of January 31, 2023 and interest rate of 12.9% 294,985 — Total notes payable 1,027,072 462,890 Total notes payable, net $ 300,000 $ 150,000

Variable Interest Entities (V_2

Variable Interest Entities (VIEs) (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of consolidated balance sheets	Schedule of consolidated balance sheets June 30, 2021 ASSETS Current Assets Cash and cash equivalents $ 2,703,028 Accounts receivable 259,457 Prepaid expenses and other assets 100,281 Total Current Assets 3,062,766 Other Assets Goodwill 31,433,526 Right of use asset, net 119,495 Intangible assets, net 6,815,522 Total Other Assets 38,368,543 Total Assets $ 41,431,309 Current Liabilities Accounts payable and accrued expenses $ 2,256,856 Lease liability - current 44,305 Total Current Liabilities 2,301,161 Long-term Liabilities Lease liability – long-term 79,659 Total Liabilities $ 2,380,820

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details)	Jun. 30, 2021USD ($)
A H A [Member]
Entity Listings [Line Items]
Cash	$ 697,191
Other current assets	2,100
Investment in ACMG	7,134,000
PHP technology	2,729,000
Loan to Clinigence	85,000
Accounts payable	(1,143,106)
Due to related party	(128,176)
Notes payable	(1,631,942)
Convertible notes payable
Goodwill	21,115,272
Purchase price	28,859,339
A H P [Member]
Entity Listings [Line Items]
Cash	3,105,877
Accounts payable	(2,683,896)
Goodwill	31,433,526
Purchase price	39,140,000
Accounts receivable	269,315
Deposits and other assets	26,178
Member relationships	6,444,000
Trademarks	$ 545,000

Organization and Basis of Pre_4

Organization and Basis of Presentation (Details Narrative)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Preferred Stock description	Pursuant to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at $2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing, the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options and warrants.

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Sales	$ 5,290,505	$ 378,588	$ 7,304,850	$ 844,218
Cost of sales	(4,187,943)	(264,859)	(5,775,416)	(463,987)
General and administrative expenses	(1,780,972)	(1,341,701)	(6,207,264)	(2,177,753)
Depreciation and amortization			(266,651)	(82,633)
Interest expense	(2,026,808)	(249,283)	(2,361,139)	(314,276)
Loss from operations	$ 936,874	$ (645,556)	5,086,797	294,359
Income from discontinued operations			0	$ 39,752
Discontinued Operations [Member]
Sales			5,958
Cost of sales			(6,795)
General and administrative expenses			(101,100)
Depreciation and amortization			(75)
Interest expense			(263)
Loss from operations			(102,275)
Gain on disposal of HealthDatix			142,027
Income from discontinued operations			$ 39,752

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2021
Office equipment and fixtures | Minimum [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years
Office equipment and fixtures | Maximum [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	7 years
Computer hardware
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Office equipment useful life	3 years
Development equipment
Property, Plant and Equipment [Line Items]
Office equipment useful life	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2021
Population Health Platform Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	11 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	15 years
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	6 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Advertising costs	$ 16,444	$ 33,791
Deferred revenue	$ 74,028		$ 76,687

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 25,402,032	$ 18,218,962
Working capital deficit	$ 1,696,785

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Office equipment and fixtures	$ 5,300	$ 5,300
Computer hardware	41,065	41,065
Computer software	16,121	16,121
Less: Accumulated depreciation	(52,119)	(50,095)
Property, Plant and Equipment, Net	$ 10,367	$ 12,391

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,024	$ 9,081

Intangible Assets (Details)

Intangible Assets (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 9,718,000
Less: Accumulated amortization	(256,175)
Intangible Assets, Net	9,461,825
Aggregate Amortization Expense	256,175
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	6,444,000
Less: Accumulated amortization	(143,200)
Intangible Assets, Net	$ 6,300,800
Intangible assets useful life	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 545,000
Less: Accumulated amortization	(30,278)
Intangible Assets, Net	$ 514,722
Intangible assets useful life	6 years
Population Health Platform Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 2,729,000
Less: Accumulated amortization	(82,697)
Intangible Assets, Net	$ 2,646,303
Intangible assets useful life	11 years

Investment in ACMG (Details Nar

Investment in ACMG (Details Narrative)	6 Months Ended
	Jun. 30, 2021USD ($)
Entity Listings [Line Items]
Investment loss	$ 139,810
A C M G [Member]
Entity Listings [Line Items]
Non-controlling interest	29.00%
Ownership Interest	$ 7,134,000
A H A [Member]
Entity Listings [Line Items]
Payment obligations	15,000,000
A C M G [Member]
Entity Listings [Line Items]
Investment loss	$ 6,994,190

Operating Lease (Details)

Operating Lease (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Operating Lease:
Operating lease right-of-use assets, net	$ 119,495	$ 0
Current portion of operating lease liabilities	44,305
Operating lease liabilities, net of current portion	$ 79,659

Operating Lease (Details 1)

Operating Lease (Details 1)	Jun. 30, 2021USD ($)
Operating Lease
2021	$ 25,229
2022	51,800
2023	53,354
2024	4,457
Total lease payments	134,840
Less: Imputed interest	10,876
Present value of lease liabilities	$ 123,964

Operating Lease (Details 2)

Operating Lease (Details 2)	Jun. 30, 2021USD ($)
Operating Lease
2021	$ 25,229
2022	51,800
2023	53,354
2024	4,457
Total minimum lease payments	$ 134,840

Operating Lease (Details 3)

Operating Lease (Details 3)	6 Months Ended
	Jun. 30, 2021USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 25,085
Right-of-use lease assets obtained in the exchange for lease liabilities:
Operating leases	$ 6,007

Operating Lease (Details Narrat

Operating Lease (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating Lease, Weighted Average Remaining Lease Term	2 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	6.75%
Continuing Operations [Member]
Rental expense	$ 47,985	$ 49,617

Earnings (Loss) Per Common Sh_3

Earnings (Loss) Per Common Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	11,324,840	1,732,687
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,890,431	1,174,814
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	8,434,409	557,873

Stock Based Compensation (Detai

Stock Based Compensation (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Options, Outstanding, Beginning Balance	1,174,814	48,854
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 1.61	$ 5.11
Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 20 days	8 years 7 months 9 days	8 years 18 days
Options, Granted	1,225,000	1,130,734
Options, Granted, Weighted Average Exercise Price	$ 1.61	$ 1.49
Options, Expired		(400)
Options, Expired, Weighted Average Exercise Price		$ 0.01
Options, Cancelled		(4,374)
Options, Cancelled, Weighted Average Exercise Price		$ 5.56
Options, Outstanding, Ending Balance	2,890,431	1,174,814	48,854
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 1.68	$ 1.61	$ 5.11
Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 1 month 9 days
Options, assumed in merger	490,617
Options, assumed in merger, Weighted Average Exercise Price	$ 2

Stock Based Compensation (Det_2

Stock Based Compensation (Details 1) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding	2,890,431	1,174,814	48,854
Number Exercisable	2,890,431
Exercise price	$ 1.68	$ 1.61	$ 5.11
Options One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Aug. 5, 2019
Number of Outstanding	40,480
Number Exercisable	40,480
Exercise price	$ 5.56
Options outstanding Expiration Date	Aug. 5, 2029
Options Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	3,600
Number Exercisable	3,600
Exercise price	$ 0.0725
Options outstanding Expiration Date	Jun. 6, 2027
Options Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 27, 2020
Number of Outstanding	307,884
Number Exercisable	307,884
Exercise price	$ 1.50
Options outstanding Expiration Date	Jan. 27, 2030
Options Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 27, 2020
Number of Outstanding	225,000
Number Exercisable	225,000
Exercise price	$ 1.50
Options outstanding Expiration Date	Jan. 27, 2027
Options Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 29, 2020
Number of Outstanding	95,794
Number Exercisable	95,794
Exercise price	$ 1.25
Options outstanding Expiration Date	Feb. 28, 2030
Options Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 11, 2020
Number of Outstanding	380,000
Number Exercisable	380,000
Exercise price	$ 1.50
Options outstanding Expiration Date	May 11, 2027
Options Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 30, 2020
Number of Outstanding	122,056
Number Exercisable	122,056
Exercise price	$ 1.45
Options outstanding Expiration Date	Jun. 30, 2030
Options 8 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 28, 2021
Number of Outstanding	1,000,000
Number Exercisable	1,000,000
Exercise price	$ 1.61
Options outstanding Expiration Date	Jan. 28, 2031
Options 9 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jan. 28, 2021
Number of Outstanding	225,000
Number Exercisable	225,000
Exercise price	$ 1.61
Options outstanding Expiration Date	Jan. 28, 2028
Options 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	290,617
Number Exercisable	290,617
Exercise price	$ 2
Options outstanding Expiration Date	Mar. 15, 2025
Options 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 2
Options outstanding Expiration Date	Feb. 25, 2031

Stock Based Compensation (Det_3

Stock Based Compensation (Details 2) - $ / shares	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Warrants, Outstanding, Beginning Balance		557,873	1,065,251
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price		$ 6.77	$ 6.04
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life		4 years 10 months 28 days	4 years 3 months 14 days	5 years 2 months 1 day
Warrants cancelled			(507,378)
Warrants cancelled			$ 0
Warrants, Outstanding, Beginning Balance	8,434,409	8,434,409	557,873	1,065,251
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 2.07	$ 2.07	$ 6.77	$ 6.04
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 9 months 14 days
Warrants, No warrant granted		1,460,571
Warrants, No warrant activity, Weighted Average Exercise Price		$ 1.75
Warrants, assumed in merger		6,415,965
Warrants, assumed in merger, Warrants, assumed in merger		$ 1.74

Stock Based Compensation (Det_4

Stock Based Compensation (Details 3)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding	8,434,409
Number Exercisable	8,434,409
Warrants One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Mar. 21, 2019
Number of Outstanding	96,433
Number Exercisable	96,433
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Apr. 30, 2019
Number of Outstanding	3,598
Number Exercisable	3,598
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 13, 2019
Number of Outstanding	14,393
Number Exercisable	14,393
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 28, 2019
Number of Outstanding	199,703
Number Exercisable	199,703
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 5, 2019
Number of Outstanding	7,197
Number Exercisable	7,197
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 25, 2019
Number of Outstanding	208,361
Number Exercisable	208,361
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Sep. 6, 2019
Number of Outstanding	25,188
Number Exercisable	25,188
Exercise price | $ / shares	$ 6.67
Expiration Date	December 31, 2024
Warrants Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Expiration Date	February 5, 2023
Warrants Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Oct. 29, 2019
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Expiration Date	April 27, 2023
Warrants 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	1,666,573
Number Exercisable	1,666,573
Exercise price | $ / shares	$ 1.55
Expiration Date	October 31, 2025
Warrants 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	48,750
Number Exercisable	48,750
Exercise price | $ / shares	$ 1.25
Expiration Date	October 31, 2025
Warrants 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	500,000
Number Exercisable	500,000
Exercise price | $ / shares	$ 4
Expiration Date	February 26, 2026
Warrants 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	1,506,452
Number Exercisable	1,506,452
Exercise price | $ / shares	$ 1.55
Expiration Date	February 1, 2027
Warrants 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Feb. 25, 2021
Number of Outstanding	2,694,190
Number Exercisable	2,694,190
Exercise price | $ / shares	$ 1.55
Expiration Date	July 31, 2026
Warrants 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 14, 2021
Number of Outstanding	651,429
Number Exercisable	651,429
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 16 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	May 28, 2021
Number of Outstanding	228,571
Number Exercisable	228,571
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 17 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 11, 2021
Number of Outstanding	182,857
Number Exercisable	182,857
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 22, 2021
Number of Outstanding	137,143
Number Exercisable	137,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 24, 2021
Number of Outstanding	169,143
Number Exercisable	169,143
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 28, 2021
Number of Outstanding	45,714
Number Exercisable	45,714
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027
Warrants 21 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Date	Jun. 29, 2021
Number of Outstanding	45,714
Number Exercisable	45,714
Exercise price | $ / shares	$ 1.75
Expiration Date	May 31, 2027

Convertible Debt (Details)

Convertible Debt (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Transfer of Financial Assets Accounted for as Sales [Line Items]
Total convertible notes payable	$ 2,155,088	$ 0
Convertible Notes Payables 1 [Member]
Transfer of Financial Assets Accounted for as Sales [Line Items]
Total convertible notes payable	1,580,088	0
Convertible Notes Payables 2 [Member]
Transfer of Financial Assets Accounted for as Sales [Line Items]
Total convertible notes payable	$ 575,000	$ 0

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Feb. 02, 2021
Entity Listings [Line Items]
Debt Instrument, Face Amount			$ 840,000
Shares price	$ 1.75	$ 1.75
Convertible Notes Payables [Member]
Entity Listings [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 2,658,960
Interest rate discount		4,906,415
Financing fees paid	$ 1,086,095	1,086,095
Convertible Notes Payables [Member] | Warrant [Member]
Entity Listings [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 3,703,134
Investor [Member]
Entity Listings [Line Items]
Shares price	$ 1.75	$ 1.75
A H A [Member] | Warrants, Granted, Weighted Average Exercise Price
Entity Listings [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 1,580,088
Debt Instrument, Face Amount	$ 7,565,375	$ 7,565,375
Shares price	$ 1.55	$ 1.55
Debt Discount (Premium)	$ 1,580,088	$ 7,565,375
Accreted balance		$ 200,000
Common stock shares		128,672
A H A [Member] | Investor [Member]
Entity Listings [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 575,000
Merger transaction description		The note was entered into on August 25, 2020 and was convertible into AHA’s common stock contingent upon a merger transaction with a SPAC, which did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313 shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. As of the date of this report, the Note has not been converted. The Company and the noteholder are renegotiating the terms of the Note.

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total notes payable	$ 1,027,072	$ 462,890
Total notes payable, net	300,000	150,000
Notes Payables 1 [Member]
Short-term Debt [Line Items]
Total notes payable	0	1,765
Notes Payables 2 [Member]
Short-term Debt [Line Items]
Total notes payable	432,087	311,125
Notes Payables 3 [Member]
Short-term Debt [Line Items]
Total notes payable	300,000	150,000
Notes Payables 4 [Member]
Short-term Debt [Line Items]
Total notes payable	$ 294,985	$ 0

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Feb. 02, 2021	Feb. 25, 2021	May 22, 2020	Apr. 21, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Short-term Debt [Line Items]
Interest rate	12.90%			1.00%
Proceeds from loan		$ 260,087		$ 311,125	$ 85,000	$ 0
Notes payable	$ 840,000				727,072		$ 312,890
Face amount	$ 840,000
Short Term Notes [Member]
Short-term Debt [Line Items]
Periodic payments					8,200
Short-term notes					$ 0		1,765
Short Term Notes [Member] | Minimum [Member]
Short-term Debt [Line Items]
Interest rate					24.00%
Short Term Notes [Member] | Maximum [Member]
Short-term Debt [Line Items]
Interest rate					31.00%
S B A Loan [Member] | A H A [Member]
Short-term Debt [Line Items]
Proceeds from loan			$ 150,000
Related Party Loan Payable [Member]
Short-term Debt [Line Items]
Notes payable					$ 432,087		$ 311,125
Related Party Loan Payable [Member] | A H A [Member]
Short-term Debt [Line Items]
Notes payable					$ 172,000
Notes Payables [Member] | A H A [Member] | Investor [Member]
Short-term Debt [Line Items]
Interest rate					12.90%
Face amount					$ 700,000
Purchase cost					$ 50,000
Exercise price					$ 1.55
Maturity date					Apr. 29, 2021
Purchase aggregate					294,985

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Feb. 25, 2021	Jan. 28, 2021	Jun. 30, 2021
Entity Listings [Line Items]
Common stock shares sold			$ 1,825,714
Shares issued price			$ 1.75
Investors for proceeds			$ 3,195,000
Placement agent			$ 319,500
Cash and issued warrants			547,715
Converted warrants			$ 200,000
Common stock shares			128,672
Officers And Employees [Member]
Entity Listings [Line Items]
Share price per share		$ 0.65
Shares issued for share based compensation, shares		228,721
Directors And Officers [Member]
Entity Listings [Line Items]
Shares issued for share based compensation, shares		153,606
A H A [Member] | Shareholders [Member]
Entity Listings [Line Items]
Common Stock Issued for acquisition, shares	14,034,472
Sale of Stock price per share	$ 2.06
Share price per share	$ 2.06
Common Stock Issued for services	750,000
A H P [Member] | Shareholders [Member]
Entity Listings [Line Items]
Common Stock Issued for acquisition, shares	19,000,000
Sale of Stock price per share	$ 2.06

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Jun. 30, 2021USD ($)
Income Tax Disclosure [Abstract]
Deferred tax liability	$ 2,429,500

Concentrations and Credit Risk

Concentrations and Credit Risk (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Product Information [Line Items]
FDIC	$ 250,000
Sales [Member] | Customers [Member]
Product Information [Line Items]
Concentration percentage	22.00%	12.00%
Sales [Member] | Customers One [Member]
Product Information [Line Items]
Concentration percentage	19.00%
Accounts Receivable [Member] | Customers [Member]
Product Information [Line Items]
Concentration percentage		14.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to related parties	$ 128,176	$ 30,000
Shareholder And Former Officer [Member]
Related Party Transaction [Line Items]
Proceeds from related party debt	$ 30,000
Maturity date	Jan. 28, 2021
Shareholder And Former Officer [Member] | Assumed Liabilities, Net [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 128,176

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	6 Months Ended
	Jun. 30, 2021USD ($)
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	$ 75,000
Elisa Luqman [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	150,000
Note payable Jerrold Young [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	180,000
Dr Hosseinion [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	250,000
Mr Sternberg [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	250,000
Mr Bowen [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	150,000
Mr Barnett [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Base Salary	$ 250,000

Variable Interest Entities (V_3

Variable Interest Entities (VIEs) (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 4,795,175	$ 26,931
Accounts receivable	334,958	18,283
Prepaid expenses and other assets	457,345	111,842
Total Current Assets	5,587,478	157,056
Goodwill	55,182,186	0
Right of use asset, net	119,495	0
Total Assets	77,355,951	169,857
Current Liabilities
Accounts payable and accrued expenses	3,810,992	695,424
Lease liability - current	44,305
Total Current Liabilities	7,284,263	1,153,652
Long-term Liabilities
Lease liability – long-term	79,659
Total Liabilities	10,093,422	$ 1,303,652
A H P I P A [Member]
Current Assets
Cash and cash equivalents	2,703,028
Accounts receivable	259,457
Prepaid expenses and other assets	100,281
Total Current Assets	3,062,766
Goodwill	31,433,526
Right of use asset, net	119,495
Intangible assets, net	6,815,522
Total Other Assets	38,368,543
Total Assets	41,431,309
Current Liabilities
Accounts payable and accrued expenses	2,256,856
Lease liability - current	44,305
Total Current Liabilities	2,301,161
Long-term Liabilities
Lease liability – long-term	79,659
Total Liabilities	$ 2,380,820

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Shares price	$ 1.75
Noteholder [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares	797,143
Investor [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Shares price	$ 1.75
Noteholder 1 [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Debt Conversion, Converted Instrument, Amount | $	$ 1,395,000